
    
      The duration of study participation depended on the status of the patient at screening:

        -  For participants receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior
           to screening, the study participation was to be approximately 17 weeks including a
           screening period of 1 week, a double-blind treatment period of 8 weeks and a follow-up
           period of 8 weeks.

        -  For participants receiving a lipid lowering treatment other than atorvastatin/ or not at
           stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive
           participants, the study participation was to be approximately 23 weeks with a screening
           period of 1 week, a run-in treatment period with atorvastatin 10 mg of 6 weeks, a
           double-blind treatment period of 8 weeks and a follow-up period of 8 weeks.
    
  